NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Satsuma Pharmaceuticals, Inc. (STSA) has a consensus analyst rating of Hold, based on 13 analysts covering the stock. Of those, 4 recommend buying, 9 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
